Endeavor Sprint
Zotarolimus-Eluting Coronary Stent System
Endeavor Sprint Zotarolimus-Eluting Coronary Stent System

Endeavor Sprint Zotarolimus-Eluting Coronary Stent System

The Endeavor® Sprint Zotarolimus-Eluting Coronary Stent System provides an enhanced delivery system and an excellent safety profile.

Healing First. Results That Last

5-Year ENDEAVOR trial pooled safety – Endeavor® stent maintains a unique safety profile.1

  • 5-year ENDEAVOR pooled safety analysis: Endeavor DES showed a very low rate of ARC definite/probable ST (Endeavor = 0.8%, BMS = 1.7%, p = 0.051), despite having only 39% of patients on DAPT at 1 year
  • Significant reduction in CD/MI vs. BMS (Endeavor 5.2% vs. BMS 8.4%, p = 0.003)

Additional Evidence Supporting Endeavor's Long-term Efficacy and Safety

  • In ENDEAVOR IV, Endeavor DES showed significant difference in clinical performance vs. Taxus® DES with a 23% significant relative risk reduction in target vessel failure (p=0.049)
  • In the ZEST study2, at 1 year, Endeavor DES was superior to Taxus DES and non-inferior to Cypher® DES in the composite primary endpoint of Death, MI and ischemia-driven TVR (Endeavor 10.1% and Taxus 14.2% p=0.003, Endeavor 10.1% and Cypher 8.3% p=0.25)

Durable Efficacy

  • In ENDEAVOR IV 82% increase in TLR with Taxus DES vs. 44% increase with Endeavor DES from years 1–3 drove similar TLR rate at 3 years3 (p = 0.747)
  • Only 0.3% increase in TLR between years 3 and 5 in ENDEAVOR II4

Reassuring Long-term Safety

  • E-Five Registry5 2-year follow-up in over 2000 real-world patients5, many with complex attributes (11.4% AMI, 30.1% diabetic), showed very low 5.1% TLR and 0.7% Arc Def/Prob. ST to 2 years (0.1% Arc Def./Prob. VLST). These results are consistent with ENDEAVOR Pooled Analysis (Pre-Approval RCT trials)
  • Significantly lower cardiac death/MI vs. BMS at 5 years (Endeavor 5.2% vs. BMS 8.4%, p = 0.003)1
  • Numerically lower ST than BMS at 5 years (Endeavor = 0.8%, BMS = 1.7%, p = 0.051)1
  • Statistically significant difference in ARC definite/probable VLST and CD/MI vs. Taxus DES in ENDEAVOR IV (p=0.004)3
  • Rapid, complete and functional healing6,7

Excellent Deliverability and Short-term Safety

  • Proven Driver® stent platform and low periprocedure/NQWMI3

Consistent Results Across Comprehensive and Robust Clinical Program

  • TLR rates and safety outcomes among real-world patients consistent with ENDEAVOR pooled analysis
  • Similar efficacy across multiple randomized clinical trials
  • More than 10,000 Endeavor DES patients in trial program1
  • Over 1200 Endeavor DES patients studied to 5 years1

References

  1. ENDEAVOR Pooled 5 year: EI (5 year); EII (5 year); EII CA (5 year); EIII (5 year); EIV (3 year); E pk (3 year)
  2. Park S, et al., ACC 2009.
  3. ENDEAVOR IV 3 year. p-Values for outcome differences are unadjusted for multiple comparisons.
  4. ENDEAVOR II 5 year Kandzari, PCR 2009
  5. E-Five Registry n=2116 prespecified subset, ACC 09
  6. 100% of Endeavor struts covered by 6 months in OCT. Guagliumi et al., ESC 2008.
  7. Haraguchi et al. TCT 2006

ENDEAVOR IV was not specifically designed or powered to individually compare VLST, CD/MI, or TLR

Enhanced Delivery System

Device Deliverability

Less force required to track in tortuosity.*

More Deliverable

  • Shorter 3-mm tip length
  • Low-profile system
  • More flexible material

Greater Flexibility

  • Softer Fulcrum balloon material

Enhanced Proximal Shaft With Increased Lubricity and Pushability

  • Surface coating increases lubricity
  • Stiffening wire improves transitioning of force

* Test conducted by measuring force required to track in a 3-dimensional tortuous model. Medtronic testing conducted with identical-sized Endeavor and Endeavor Sprint stent systems.

Last updated: 26 Feb 2013

Medtronic Vascular

(877) 526-7890